Last updated on March 2020

European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Collagen Vascular Diseases | Collagen disease | Familial Benign Hematuria | Pediatric Kidney Disease | Alport's Syndrome | Thin Basement Membrane Disease | Nephritis | Hereditary Kidney Disease
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria/ Exclusion Criteria:

The diagnosis of Alport syndrome (AS) was proven by kidney biopsy or mutation analysis (or both). Patients were included if they were affected males with X-linked AS or patients with genetically proven homozygous autosomal AS. Patients were excluded if they did not give informed consent or the diagnosis was suspected but not confirmed.

The diagnosis of the heterozygous status was proven by (1) mutation analysis or (2) kidney biopsy plus genetic consultation for decision in between XLAS or ARAS inheritance (including a conclusive genealogic tree and/or linkage analysis). Patients were excluded if they were affected males with XLAS or patients with genetically proven homozygous ARAS. Patients were excluded if they did not give informed consent or the diagnosis was suspected but not confirmed or if they donated a kidney (living donor to affected family member).

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.